Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;18(3):509-13.
doi: 10.3233/JAD-2009-1183.

Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology

Lidia Glodzik  1 , Susan De Santi, Kenneth E Rich, Miroslaw Brys, Elizabeth Pirraglia, Rachel Mistur, Remigiusz Switalski, Lisa Mosconi, Martin Sadowski, Henrik Zetterberg, Kaj Blennow, Mony J de Leon
Affiliations

Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology

Lidia Glodzik et al. J Alzheimers Dis. 2009.

Abstract

Previous studies showed that memantine inhibits tau hyperphosphorylation in vitro. In this study, phosphorylated tau (P-tau) and total tau (T-tau) were measured before and after 6 month treatment with memantine in 12 subjects ranging from normal cognition with subjective memory complaints, through mild cognitive impairment to mild Alzheimer's disease. Thirteen non-treated individuals served as controls. Treatment was associated with a reduction of P-tau in subjects with normal cognition. No treatment effects were seen among impaired individuals, suggesting that longer treatment time may be necessary to achieve biomarker effect in this group.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Rate of change in T-tau plotted against rate of change in P-tau. Rates of change in biomarkers are presented as: Biomfollow-up-Biombaseline/time between exams in months (pg/mL per month).
See this image and copyright information in PMC

References

    1. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1:101–110. - PMC - PubMed
    1. Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol. 2006;17:411–424. - PubMed
    1. Chan SF, Sucher SJ. An NMDA receptor signaling complex with protein phosphatase 2A. J Neurosci. 2001;20:7985–7992. - PMC - PubMed
    1. Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord. 2008;25:408–422. - PubMed
    1. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566:261–269. - PubMed

Publication types

MeSH terms